Kimball Electronics (KE) Q2 2026 earnings review
Guidance Raise Signals Turnaround Despite Revenue Dip
Kimball Electronics is executing a 'shrink to grow' strategy that is beginning to pay off. While headline revenue fell 5% YoY due to known Automotive weakness and divestitures, the company raised its full-year guidance for both Revenue and Operating Margins. The bullish signal is driven by the Medical segment, which accelerated to 15% growth, and improved operational efficiency that pushed Adjusted Operating Margins to 4.5% (up 80bps YoY).
🐂 Bull Case
The strategic pivot is working. Medical sales grew 15% YoY and now comprise 28% of total revenue. With the new Indianapolis facility opening, management expects this high-margin vertical to continue outcompeting other segments.
Despite lower sales, profitability improved significantly. Adjusted Operating Margin expanded to 4.5% from 3.7% last year, proving that the mix shift toward Medical and away from low-margin Industrial/Auto work is accretive.
🐻 Bear Case
Automotive remains the largest segment ($162M) and is shrinking (-13% YoY). The loss of the braking program and general EV softness continue to weigh heavily on the top line.
Industrial sales (excluding divested AT&M) fell 5% YoY. While less severe than Automotive, the lack of recovery here puts more pressure on Medical to carry the entire growth narrative.
⚖️ Verdict: 🟢
Bullish. Raising guidance in a murky macro environment is a strong confidence signal. The divergence between the surging Medical segment and the shrinking legacy Automotive business suggests the company's mix-shift strategy is successfully improving earnings quality.
Key Themes
Medical Segment Acceleration
Accelerating. Medical revenue growth has ramped up consistently: +2% (25Q3) -> +5% (25Q4) -> +13% (26Q1) -> +15% (26Q2). The company is capitalizing on its role as a Contract Manufacturing Organization (CMO), supported by the grand opening of its Indianapolis facility.
Operational Efficiency
Improving. The company demonstrated significant operating leverage. While Gross Profit margins improved to 8.2% (vs 6.6% in 25Q2), the real story is the discipline in execution, allowing them to raise full-year margin guidance. Cash from operations was positive for the 8th consecutive quarter.
Automotive Headwinds
Decelerating/Negative. Automotive sales dropped 13% YoY. This is a continuation of the trend seen in 26Q1 (-10%). The segment is suffering from the previous loss of a braking program and broader sector inventory adjustments. Until this segment stabilizes, it puts a ceiling on total company growth.
Rebranding to 'Kimball Solutions'
Management announced a rebrand to 'Kimball Solutions' to reflect expanded capabilities beyond pure manufacturing, particularly in the medical vertical. This aligns with the opening of the Indianapolis facility and the shift toward higher-value services.
Other KPIs
Stable. Slightly down from $0.29 in the prior year, but notably better than the $0.14 GAAP EPS, reflecting significant adjustments for restructuring and stock compensation.
Stable. Inventory increased slightly from $273.5M at year-end (June 30) but remains well below the peak levels of >$330M seen in FY24, indicating continued working capital discipline.
Decelerating. Down significantly from $74.9M in the prior year period. While Q2 marked the 8th consecutive positive quarter, the magnitude of cash generation has slowed compared to the aggressive inventory unwind of FY25.
Guidance
Accelerating (Outlook). The range was raised from the previous $1,350-$1,450M. The midpoint increased from $1,400M to $1,430M. This implies confidence in the second half of the fiscal year, likely driven by Medical strength.
Accelerating (Outlook). Guidance raised from the prior 4.0%-4.25%. This suggests that the margin expansion seen in Q2 (4.5%) is sustainable and not just a quarterly fluctuation.
Stable. Unchanged from prior guidance. The spending is heavily weighted toward the new Indianapolis medical facility.
Key Questions
Guidance Raise Drivers
You raised revenue guidance by ~$30M at the midpoint. Is this entirely driven by the Medical vertical outperformance, or are you seeing stabilization in the Automotive channel earlier than expected?
Medical Margin Profile
With Medical growing to nearly 30% of sales and driving the guidance raise, does the new Indianapolis facility introduce near-term margin drag due to ramp-up costs, or is the mix shift immediately accretive?
Automotive Bottom
Automotive has been down double-digits for consecutive quarters (-10% Q1, -13% Q2). Do you have visibility into a trough for this segment in the second half of FY26?
Cash Flow Dynamics
Operating cash flow for the first six months was $14.9M versus $74.9M last year. As you return to growth in Medical, should we expect working capital builds to constrain free cash flow for the remainder of FY26?